ClinicalTrials.gg
RecruitingNCT06370481HEATUpdated Feb 18, 2026

HIV, Equity, and Addiction Training (HEAT) Program

An interventional study of Telemedicine and Standard of care in Substance Use Disorders, Hiv and Opioid Use Disorder, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Primary conditionOpioid-Related DisordersRegistry: Substance-Related DisordersReclassifiedWhy we changed it
Registry
Substance-Related Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Opioid-Related Disorders
Why
  1. The study's listed conditions name Opioid-Related Disorders, a narrower term within Substance-Related Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham — 5 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · University of Alabama at Birmingham.

Started
2026
with 1 other
No phase
4 of 10
3 open now
Registered
6th of 10
by date

Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, this one is one of 2 that started in 2026, is one of 4 with no phase, and was the 6th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

5 of the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama.

Read the detailed description

The contemporary drug crisis and the COVID-19 pandemic have exposed the complex syndemics of addiction and infectious diseases: rising rates of substance use disorder (SUD) have outpaced our ability to respond with a limited healthcare workforce and public health capacity. SUD is increasing in those living with and at risk for HIV, and infectious consequences of SUD, like hepatitis C, have continued, unmitigated, in rural parts of the U.S. where many states lack Medicaid expansion, syringe service programs, and public health infrastructure to respond to the drug crisis and comorbid infections. Systemic racism and regressive policies in the Deep South criminalize people who use drugs, creating additional barriers to care, HIV prevention, and addiction treatment. As a result, people who use drugs rarely receive comprehensive addiction and HIV treatment. Yet telemedicine has the potential to overcome these barriers and bypass the constraints of a brick-and-mortar clinic to link vulnerable people, including those with HIV, to care. Although telemedicine has become mainstream in recent years, few studies have evaluated telemedicine for SUD in the Deep South from the perspective of patients and providers.

03

Conditions studied

  • Substance Use Disorders
  • Hiv
  • Opioid Use Disorder
  • Stimulant Use (Diagnosis)

Keywords

  • Alabama
  • Ryan White Clinics
  • HIV treatment
  • Substance use disorder treatment
  • Telemedicine
04

In context

Opioid-Related Disorders Reclassified

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

This study's planned enrollment of 30 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Compared within Opioid-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving services at clinics in Alabama
  • Reported opioid and/or stimulant misuse
  • 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Receipt of SUD clinical care other than through provider/clinic in the last 3 months
  • Inability to engage in interviews independently without support (e.g., cognitive impairment)
  • Currently psychotic
  • Actively suicidal: presents with a suicide attempt or suicidal ideation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients living with HIV and substance use

    Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.

    Other: Telemedicine · Other: Standard of care

Interventions

  • OtherTelemedicine

    Routine care administered via telemedicine

  • OtherStandard of care

    Standard of care, as received in HIV clinic settings

07

What researchers measure

Primary outcomes

  1. Percent of participants who have a follow-up healthcare visit

    Follow up visit for care (either telemedicine or in person)

    Time frame: 1 month, 2 months, 3 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — The research will comply with the NIH Data Sharing policy and will coordinate collection and sharing of key data. Data are available upon request from the public and research community after main findings are published. To request data, the investigators ask that interested parties submit a detailed description of the aims and methods of their research to the PI, including contact information from the primary requester, institutional affiliation, current CV and qualifications, sources of financial support, and conflict of interest statement. The MPIs will review requests as submitted and determine the appropriateness of the request with collaborators or if additional safeguards are needed. Upon approval, data transfer agreements must be established and proof of IRB approval from the requester's institutional IRB must be presented. Our team will comply with HIPAA and Common Rule de-identification prior to data sharing to ensure protection of study participants

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Available after studies are published and will be maintained for 5 years after study end date.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 35 months is above that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Jan 29, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06370481
Responsible party
Ellen Eaton (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 17, 2024
Start date
Jan 29, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Feb 18, 2026

Study contacts

Ellen F Eaton, MD, MSPH
Contact
eeaton@uabmc.edu
2059750661
Stephen Tyler O'Rear
Contact
storear@uabmc.edu
2057214060
Ellen F Eaton, MD, MSPH
principal investigator · University of Alabama at Birmingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion